St. Jude Care & Treatment

Menu

Close

Recruiting

1922CAR: Cell Therapy for Acute Lymphoblastic Leukemia

About this study

1922CAR is a study that uses chimeric antigen receptor T cell (CAR T) therapy for children and young adults with acute lymphoblastic leukemia (ALL) that has returned or has not responded to treatment.

CAR T cell therapy combines 2 of the ways the body’s immune system fights disease and infection: antibodies and T cells. It is a type of immunotherapy.

In this study, cells from the patient’s blood are collected and changed in the lab so that they can recognize certain substances (called CD19 and CD22) on the surface of cancer cells. The patient’s cells are given back to them by an infusion into their blood. These infused cells can recognize, attack, and kill cancer cells.

Patients will be given chemotherapy before the infusion so their bodies will accept the CAR T cells.

Patients will be followed for 15 years after treatment and receive tests and procedures such as blood tests, bone marrow tests, and radiology scans when needed.

 Eligibility overview

  • Up to age 21
  • Relapsed or refractory CD19- and/or CD22-positive acute leukemia

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients with Acute Lymphoblastic Leukemia (1922CAR)

Study goal:

To study the side effects of CAR T cells, find the safest and most effective dose, see how long the CAR T cells last in the body, and find out how well the therapy works in people with refractory or relapsed acute lymphoblastic leukemia.

Diagnosis:

Acute lymphoblastic leukemia

Age:

Up to age 21

Clinical trials categories:

Childhood Cancer Acute Lymphoblastic Leukemia (ALL)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more